Viatris (VTRS) Current Assets (2019 - 2026)
Viatris (VTRS) posted Current Assets of $10.1 billion for Q2 2026, down 7.89% on a QoQ basis from $10.9 billion in Q1 2026, and up 2.88% year-over-year from $9.8 billion in Q2 2025.
Analysis
Viatris (VTRS) Current Assets (2019 - 2026) Analysis & Trends
Viatris has reported Current Assets for 8 years, with the latest figure at $10.1 billion in Q2 2026.
- On a quarterly basis, Current Assets rose 2.88% year-over-year to $10.1 billion in Q2 2026; TTM through Jun 2026 was $10.1 billion, a 2.88% increase from a year earlier, with the FY2025 full-year figure at $9.8 billion, up 2.82% from the prior year.
- Current Assets was $10.1 billion for Q2 2026 at Viatris, down from $10.9 billion in the prior quarter.
- The five-year high for Current Assets was $13.0 billion in Q4 2023, with the low at $9.5 billion in Q4 2024.
- Average Current Assets over 5 years is $10.7 billion, with a median of $10.6 billion recorded in 2022.
- The largest YoY upside for Current Assets was 34.2% in 2024 against a maximum downside of 26.63% in 2024.
- Over 5 years, Current Assets stood at $10.6 billion in 2022, then gained by 22.01% to $13.0 billion in 2023, then retreated by 26.63% to $9.5 billion in 2024, then grew by 2.82% to $9.8 billion in 2025, then gained by 2.72% to $10.1 billion in 2026.
- The last three Current Assets figures came in at $10.1 billion (Q2 2026), $10.9 billion (Q1 2026), and $9.8 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 13.76 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 10.06 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 3.16 Bn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 1.95 Bn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 6.52 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 544.97 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 825.43 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 630.95 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 72.50 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | 6.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.06 Bn |
| Mar 31, 2026 | 10.92 Bn |
| Dec 31, 2025 | 9.79 Bn |
| Sep 30, 2025 | 9.95 Bn |
| Jun 30, 2025 | 9.77 Bn |
| Mar 31, 2025 | 9.62 Bn |
| Dec 31, 2024 | 9.52 Bn |
| Sep 30, 2024 | 11.31 Bn |
| Jun 30, 2024 | 11.79 Bn |
| Mar 31, 2024 | 12.92 Bn |
| Dec 31, 2023 | 12.98 Bn |
| Sep 30, 2023 | 10.93 Bn |
| Jun 30, 2023 | 9.78 Bn |
| Mar 31, 2023 | 9.63 Bn |
| Dec 31, 2022 | 10.64 Bn |
| Sep 30, 2022 | 10.49 Bn |
| Jun 30, 2022 | 11.18 Bn |
| Mar 31, 2022 | 11.74 Bn |
| Dec 31, 2021 | 10.90 Bn |
| Sep 30, 2021 | 11.31 Bn |